Imidazole derivatives
US6288061A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 21, 2000 |
| Grant date | Sep 11, 2001 |
| Priority date | — |
| Expiry date | Jun 21, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to the imidazole derivative of the following formula (I) ##STR1## wherein R.sup.1 is hydrogen, optionally substituted alkyl and the like, R.sup.2 is hydrogen, optionally substituted alkyl and the like, R.sup.3 is optionally substituted heteroaryl, R.sup.4 is optionally substituted cycloalkyl, optionally substituted phenyl and the like, provided that when R.sup.1 is hydrogen, and R.sup.2 and R.sup.4 are the same or different and each is phenyl or phenyl substituted by halogen atom, lower alkyl or lower alkoxy, R.sup.3 is benzothiazolyl or thiazolyl substituted by phenyl, the imidazole derivative of the following formula (XII) ##STR2## wherein R.sup.6 is optionally substituted phenyl or optionally substituted heteroaryl and R.sup.7 is substituted phenyl, and pharmaceutically acceptable salts thereof. The compounds of the formulas (I) and (XII) and pharmaceutically acceptable salts thereof of the present invention inhibit IL-4 and IL-5 production by Th2 cells and are effective for the prophylaxis and treatment of allergic diseases such as atopic dermatitis, bronchial asthma, allergic rhinitis and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.